Form 4: Kymera Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Brian Adams, Chief Legal Officer of Kymera Therapeutics, Inc., sold 6,371 shares of common stock on September 4, 2026.
Summary
- Open-market sale: disposed of 1,209 Common Stock at $115.55 ($139,700) on September 4, 2026; holds 55,416 after (Direct).
- Open-market sale: disposed of 3,025 Common Stock at $116.81 ($353,350) on September 4, 2026; holds 52,391 after (Direct).
- Open-market sale: disposed of 2,137 Common Stock at $117.57 ($251,247) on September 4, 2026; holds 50,254 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $744,297 of stock on the open market.
Insider Transactions
Brian Adams — Officer (Chief Legal Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Open-market sale | Common Stock | 1,209 | $116 | $139.7K | 55,416 |
| 2026-09-04 | Open-market sale | Common Stock | 3,025 | $117 | $353.4K | 52,391 |
| 2026-09-04 | Open-market sale | Common Stock | 2,137 | $118 | $251.2K | 50,254 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Open-market sale (1,209 shares) |
| 2026-09-04 | Open-market sale (3,025 shares) |
| 2026-09-04 | Open-market sale (2,137 shares) |
Keywords
insider transaction, Form 4, KYMR, Kymera Therapeutics, Inc., bearish, Brian Adams
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.